Recent Advances in Development of Kaposi's Sarcoma‐Associated Herpesvirus‐Latency‐Associated Nuclear Antigen Targeted Therapies

Kaposi's Sarcoma‐associated Herpesvirus (KSHV, also named as Human Herpesvirus 8, HHV‐8) represents a principal causative agent of several cancers arising in patients with compromised immune systems. The latency‐associated nuclear antigen (LANA), encoded by KSHV ORF73, is required for replication, persistence, and gene transcription of the viral KSHV genome. Also, LANA functions contribute to KSHV‐induced angiogenesis, oncogenesis, cell proliferation and immune escape. Therefore, LANA represents a promising target for the discovery and development of new anti‐KSHV drugs, although no specific treatments directed against KSHV latency are available. In the current review, we summarize recent advances in development of KSHV‐LANA targeted therapies and discuss existed challenging as well as potential concerns.